Forbion invests USD 2.3M in seed financing of CoviCept Therapeutics, Inc.

Forbion, a leading European life sciences venture capital firm, today announces a $2.3m seed investment in newly formed CoviCept Therapeutics, Inc. (“CoviCept”), a California-based company that is developing a small molecule that inhibits the replication of SARS-CoV-2 (COVID-19) and other RNA viruses. CoviCept was founded by Sam Tsimikas, Philip Gordts and Jeffrey Esko, all from the University of California San Diego. The Company’s aim is to initiate a first clinical study in the second half of 2021. About Forbion Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands, Germany and Singapore. Forbion invests in life sciences companies that are active in the (bio-) pharmaceutical space. About CoviCept Therapeutics, Inc. CoviCept Therapeutics, Inc. is a newly founded company based in San Diego, USA, focused on the development of a small molecule that inhibits the replication and spread of RNA viruses, including SARS-Cov-2.
（以上内容由医药魔方AI生成）